SHANGHAI KAIRUN BIOLOGY MEDICINE LIMITED LIABILITY +1
View PDF2 Cites 15 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
There are many kinds of anticoagulant drugs available, but most of them are western anticoagulant drugs with relatively large side effects. When using them, the blood coagulation status needs to be checked repeatedly to avoid bleeding. In addition, the administration methods are complicated. Drugs are a safety hazard
For example, currently widely used anticoagulant drugs such as heparin, low-molecular-weight heparin, and warfarin need to detect blood coagulation status during use. Excessive use or use by people with different physiques can easily cause various bleedings, posing serious safety risks.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0029] Extraction of sea cucumber glycosaminoglycans:
[0030] Weigh 5 kg of Yuzu sea cucumber medicinal material and soak in water overnight. Drain the body wall of the sea cucumber, mince it, weigh it and add water to 40Kg, put it in a water bath at 60°C, add 6mol / L sodium hydroxide to adjust the pH to 8.0±0.2, add 100ml of protease Alcalase (Novozymes (Shenyang) Biotechnology Co., Ltd.) stirring, enzymatic hydrolysis for 4 hours, inactivation above 85°C for 10 minutes, cooling to 50°C±2°C, adding 6mol / L sodium hydroxide to adjust the pH to 8.0±0.2, and adding 10g of compound trypsin (Wuxi City Xuemei Enzyme Preparation Technology Co., Ltd. (Xuemei Brand) stirred for 4 hours, boiled for 10 minutes, and cooled. Centrifuge at 4°C, collect the supernatant, add 6mol / L hydrochloric acid to adjust the pH to 2.5±0.2, refrigerate at 4°C for 2 hours, centrifuge, collect the supernatant, add 6mol / L sodium hydroxide to adjust the pH to 7.0±0.2, add 0.8 double ethanol, and let stand o...
Embodiment 2
[0041] Pharmacodynamic experiment of depolymerized sea cucumber glycosaminoglycan
[0042] 2.1 In vitro anticoagulation experiment
[0043] 2.1.1 Test material
[0044] Samples for testing:
[0045] Name: depolymerized sea cucumber glycosaminoglycan (26,000Da~45,000Da), the following abbreviation: DHG;
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention discloses an application of depolymerized holothurian glycosaminolycan in preparation of a medicine for preventing and treating thromboembolism diseases. The depolymerized holothurian glycosaminolycan is more than one of depolymerized holothurian glycosaminolycan with weight-average molecular weight of 26000Da-45000Da. In intravenous injection or subcutaneous injection of the medicine utilizing the depolymerized holothurian glycosaminolycan with weight-average molecular weight of 26000Da-45000Da as an active ingredient, the medicine has excellent anticoagulation effect and small side effect, thereby being capable of being effectively used for preventing and treating thromboembolism diseases. With dosage increase, the blood coagulation time of the injection of the depolymerized holothurian glycosaminolycan with weight-average molecular weight of 26000Da-45000Da is prolonged and the anticoagulation effect is enhanced, and the medicine is dosed by subcutaneous injection to better facilitate the medicine utilization and improve the medicine utilization convenience and security at the same time.
Description
technical field [0001] The invention relates to a medical application of depolymerized sea cucumber glycosaminoglycan, in particular to the application of depolymerized sea cucumber glycosaminoglycan with a weight average molecular weight of 26,000Da to 45,000Da in the preparation of medicines for preventing and treating thromboembolic diseases, including arterial Atherosclerotic thrombotic diseases and venous thromboembolic diseases, as well as the application of anti-thrombotic drugs after surgery. Background technique [0002] The blood viscosity of middle-aged and elderly people often gradually increases, and the possibility of platelet aggregation leading to thrombus (such as coronary artery and cerebral artery) increases. Thromboembolic disease has become a common disease that seriously threatens the health of human beings, especially middle-aged and elderly people. disease. Thrombosis is the main cause of arterial diseases such as myocardial infarction and stroke, as...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more